by Patricia Weiss and Ludwig Burger
作者：帕特里夏·韋斯和路德維希·伯格
Ingelheim, Germany, April 16 (Reuters) - Boehringer Ingelheim on Tuesday Overtook Bayer Baygn.de as Germany's Largest Drugmaker When the Unlisted Company Reported a Currency-Adjusted Gain in 2023 Pharmaceutical Sales of 10.3% to 20.8 Billion Euros ($22.11 Billion).
德國英格爾海姆4月16日電（路透社）——勃林格·英格爾海姆週二超越了拜耳 baygn.de 作爲德國最大的製藥商，這家非上市公司報告稱，2023年經匯率調整後的藥品銷售額增長了10.3％，達到208億歐元（合221.1億美元）。
Diversified Rival Bayer Reported in March That 2023 Sales at Its Pharmaceuticals Division Slipped 6% to 18.1 Billion Euros, as Gains From Prostate Cancer Drug Nubeqa and Kidney Drug Kerendia Were Offset by Declines in China.
多元化競爭對手拜耳在3月份報告稱，由於前列腺癌藥物Nubeqa和腎臟藥物Kerendia的收益被中國的下跌所抵消，其製藥部門2023年銷售額下降了6％，至181億歐元。
Growth at Boehringer's Pharma Unit, Driven by Diabetes Drug Jardiance and Lung Drug Ofev, Pushed 2023 Group Sales, Also Including Its Animal Health Business, up 9.7% at Constant Currencies to 25.6 Billion Euros.
在糖尿病藥物Jardiance和肺部藥物Ofev的推動下，勃林格製藥部門的增長推動了2023年集團的銷售額，包括其動物健康業務，按固定貨幣計算，增長了9.7％，達到256億歐元。
Boehringer's Jardiance Group of Products, Managed in a Partnership With Eli Lilly Lly.n, Made 7.4 Billion Euros in Annual Sales, a Currency-Adjusted Surge of 31%. Jardiance, Used to Treat Diabetes, Heart Failure and Chronic Kidney Disease, Competes With Astrazeneca's Azn.l Farxiga.
勃林格旗下的Jardiance產品集團，由禮來公司合作管理 lly.n，年銷售額爲74億歐元，經匯率調整後增長了31％。用於治療糖尿病、心力衰竭和慢性腎臟病的Jardiance與阿斯利康競爭 azn.l Farxiga。
Sales of Pulmonary Fibrosis Drug Ofev Rose a Currency-Adjusted 12.8% to 3.5 Billion Euros, Boehringer Said.
勃林格說，經匯率調整後，肺纖維化藥物Ofev的銷售額增長了12.8％，達到35億歐元。
Boehringer Is in a Collaboration With Denmark's Zealand Pharma Zela.co to Develop a Weight Loss Drug That the Partners Hope Can Be Launched in 2027 or 2028, to Compete With Lilly's Recently Launched Obesity Drug Mounjaro.
勃林格正在與丹麥的新西蘭製藥公司合作 Zela.co 制定減肥計劃 毒品 合作伙伴希望能夠在2027年或2028年推出，以與禮來最近推出的肥胖藥物Mounjaro競爭。
for 2024, Boehringer Said It Expects a Slight Increase in Group Revenues, Adjusted for Currency Swings and One-off Effects.
勃林格表示，經匯率波動和一次性影響調整後，預計2024年的集團收入將略有增加。
($1 = 0.9409 Euros)
($1 = 0.9409 歐元)
(Reporting by Patricia Weiss and Ludwig Burger, Editing by Rachel More)
（帕特里夏·魏斯和路德維希·伯格的報道，雷切爾·莫爾編輯）
((Ludwig.burger@Thomsonreuters.com; +49 30 220133634;))
((Ludwig.burger@Thomsonreuters.com; +49 30 220133634;))